C. W. Yancy, M. Jessup, B. Bozkurt, J. Butler, D. E. Casey et al., ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America, J Am Coll Cardiol, vol.70, issue.6, pp.776-803, 2017.

B. Pitt, M. A. Pfeffer, S. F. Assmann, R. Boineau, I. S. Anand et al., Spironolactone for heart failure with preserved ejection fraction, N Engl J Med, vol.370, issue.15, pp.1383-92, 2014.

M. A. Pfeffer, B. Claggett, S. F. Assmann, R. Boineau, I. S. Anand et al., Regional Variation in Patients and Outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) Trial, Circulation, vol.131, issue.1, pp.34-42, 2015.

S. De-denus, E. O'meara, A. S. Desai, B. Claggett, E. F. Lewis et al., Spironolactone Metabolites in TOPCAT -New Insights into Regional Variation, N Engl J Med, vol.376, issue.17, pp.1690-1692, 2017.

J. P. Ferreira, N. Girerd, P. Rossignol, and F. Zannad, Geographic differences in heart failure trials, Eur J Heart Fail, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01745546

J. Tromp, J. P. Ferreira, S. Janwanishstaporn, M. Shah, B. Greenberg et al., Heart failure around the world, Eur J Heart Fail, 2019.

B. Pitt, F. Zannad, W. J. Remme, R. Cody, A. Castaigne et al., The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators, N Engl J Med, vol.341, issue.10, pp.709-726, 1999.

P. Ponikowski, A. A. Voors, S. D. Anker, H. Bueno, J. G. Cleland et al., ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC), Eur J Heart Fail, 2016.

F. Zannad, J. J. Mcmurray, H. Krum, D. J. Van-veldhuisen, K. Swedberg et al., Eplerenone in patients with systolic heart failure and mild symptoms, N Engl J Med, vol.364, issue.1, pp.11-21, 2011.
URL : https://hal.archives-ouvertes.fr/hal-01742988

J. P. Ferreira, P. Abreu, J. J. Mcmurray, D. J. Van-veldhuisen, K. Swedberg et al., Renal function stratified dose comparisons of eplerenone versus placebo in the EMPHASIS-HF trial, Eur J Heart Fail, vol.21, issue.3, pp.345-351, 2019.

A. S. Desai, J. Liu, M. A. Pfeffer, B. Claggett, J. Fleg et al., Incident Hyperkalemia, Hypokalemia, and Clinical Outcomes During Spironolactone Treatment of Heart Failure With Preserved Ejection Fraction: Analysis of the TOPCAT Trial, J Card Fail, vol.24, issue.5, pp.313-320, 2018.

M. Vaduganathan, B. L. Claggett, N. A. Chatterjee, I. S. Anand, N. K. Sweitzer et al., Sudden Death in Heart Failure With Preserved Ejection Fraction: A Competing Risks Analysis From the TOPCAT Trial, JACC Heart Fail, vol.6, issue.8, pp.653-661, 2018.

B. T. Santema, W. Ouwerkerk, J. Tromp, I. E. Sama, A. Ravera et al., Identifying optimal doses of heart failure medications in men compared with women: a prospective, observational, cohort study, Lancet, vol.2019, pp.1254-1263, 10205.

P. Rossignol, D. Dobre, J. J. Mcmurray, K. Swedberg, H. Krum et al., Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF), Circ Heart Fail, vol.7, issue.1, pp.51-59, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01739545

P. Rossignol and J. P. Ferreira, Balancing Benefits and Risks of Spironolactone in HFpEF and Chronic Kidney Disease Patients: Mind the Gap of Biological Monitoring! JACC Heart Fail, vol.7, pp.33-35, 2019.

R. Eschalier, J. J. Mcmurray, K. Swedberg, D. J. Van-veldhuisen, H. Krum et al., Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure), J Am Coll Cardiol, vol.62, issue.17, pp.1585-93, 2013.

P. Rossignol, S. Masson, S. Barlera, N. Girerd, A. Castelnovo et al., Loss in body weight is an independent prognostic factor for mortality in chronic heart failure: insights from the GISSI-HF and Val-HeFT trials, Eur J Heart Fail, vol.17, issue.4, pp.424-457, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01752255

S. Stienen, J. P. Ferreira, N. Girerd, K. Duarte, Z. Lamiral et al., Mean BMI, visit-to-visit BMI variability and BMI changes during follow-up in patients with acute myocardial infarction with systolic dysfunction and/or heart failure: insights from the High-Risk Myocardial Infarction Initiative, Clin Res Cardiol, vol.108, issue.11, pp.1215-1225, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02510907

G. Savarese, H. Xu, M. Trevisan, U. Dahlstrom, P. Rossignol et al., Incidence, Predictors, and Outcome Associations of Dyskalemia in Heart Failure With Preserved, Mid-Range, and Reduced Ejection Fraction, JACC Heart Fail, vol.7, issue.1, pp.65-76, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02510424

A. Olivier and A. Pizard, Effect of eplerenone in patients with heart failure and reduced ejection fraction: Potential effect modification by abdominal obesity. Insight from EMPHASIS-HF trial, European Journal of Heart Failure, 2017.

M. Packer, P. A. Poole-wilson, P. W. Armstrong, J. G. Cleland, J. D. Horowitz et al., Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure, ATLAS Study Group. Circulation, vol.100, issue.23, pp.2312-2320, 1999.

M. A. Konstam, J. D. Neaton, K. Dickstein, H. Drexler, M. Komajda et al., Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial, Eur Heart J, vol.374, issue.9704, pp.481-490, 1998.

M. R. Bristow, E. M. Gilbert, W. T. Abraham, K. F. Adams, M. B. Fowler et al., Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators, Circulation, vol.94, issue.11, pp.2807-2823, 1996.

C. N. Marti, G. C. Fonarow, S. D. Anker, C. Yancy, M. Vaduganathan et al., Medication dosing for heart failure with reduced ejection fraction -opportunities and challenges, Eur J Heart Fail, vol.21, issue.3, pp.286-296, 2019.

P. H. Lam, D. J. Dooley, G. C. Fonarow, J. Butler, D. L. Bhatt et al., Similar clinical benefits from below-target and target dose enalapril in patients with heart failure in the SOLVD Treatment trial, Eur J Heart Fail, vol.20, issue.2, pp.359-369, 2018.

I. E. Beldhuis, P. L. Myhre, B. Claggett, K. Damman, J. C. Fang et al., Efficacy and Safety of Spironolactone in Patients With HFpEF and Chronic Kidney Disease, JACC Heart Fail, vol.7, issue.1, pp.25-32, 2019.

B. Claggett, S. Pocock, L. J. Wei, M. A. Pfeffer, J. J. Mcmurray et al., Comparison of Time-to-First Event and Recurrent-Event Methods in Randomized, Clinical Trials. Circulation, vol.138, issue.6, pp.570-577, 2018.

B. Pitt, S. D. Anker, D. A. Bushinsky, D. W. Kitzman, F. Zannad et al., Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebocontrolled study in patients with chronic heart failure (the PEARL-HF) trial, Eur Heart J, vol.32, issue.7, pp.820-828, 2011.

F. Zannad, J. P. Ferreira, and B. Pitt, Potassium binders for the prevention of hyperkalaemia in heart failure patients: implementation issues and future developments, Eur Heart J Suppl, vol.21, pp.55-60, 2019.

G. Filippatos, S. D. Anker, M. Bohm, M. Gheorghiade, L. Kober et al., A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease, Eur Heart J, 2016.

J. P. Ferreira, S. Kraus, S. Mitchell, P. Perel, D. Pineiro et al., World Heart Federation Roadmap for Heart Failure, Glob Heart, vol.14, issue.3, pp.197-214, 2019.

J. P. Ferreira, R. J. Mentz, A. Pizard, B. Pitt, and F. Zannad, Tailoring mineralocorticoid receptor antagonist therapy in heart failure patients: are we moving towards a personalized approach, Eur J Heart Fail, 2017.